FrancophonIA/ELRC3.0 huggingface dataset:
English: Tc) besilesomab solution obtained is indicated in adults for scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis.
Slovenian: Po radioaktivnem označevanju z raztopino natrijevega (99mTc) pertehnetata je dobljena raztopina tehnecijevega (99mTc) besilesomaba indicirana pri odraslih bolnikih za scintigrafsko slikanje skupaj z drugimi primernimi načini slikanja za določanje mesta vnetja/okužbe v perifernih kosteh pri odraslih s sumom na osteomielitis.
English: Scintimun: white powder Solvent for Scintimun: white powder
Slovenian: FARMACEVTSKA OBLIKA komplet za pripravo radiofarmaka Scintimun: bel prašek Vehikel za zdravilo Scintimun: bel prašek
English: - Keep this leaflet.
Slovenian: Previdno premešajte.
English: Close contact with infants and pregnant women should be restricted during the first 12 hours after the injection.
Slovenian: V prvih 12 urah po injiciranju je treba omejiti tesni stik z dojenčki in nosečnicami.
English: 1, 1, 3, 3-propane tetraphosphonic acid, tetrasodium salt, dihydrate (PTP) Stannous chloride dihydrate
Slovenian: 1,1,3,3-propantetrafosfonska kislina, tetranatrijeva sol, dihidrat (PTP) kositrov klorid dihidrat natrijev hidroksid / klorovodikova kislina dušik
English: Close contact with infants should be restricted during the first 12 hours after the injection.
Slovenian: V prvih 12 urah po injiciranju je treba omejiti tesni stik z dojenčki.
English: Apply a spot (2 µL) of the radiolabelled solution to the starting line of the ITLC-SG or RBM-1 paper strip using a syringe and a needle.
Slovenian: Z brizgo in iglo na začetno črto ITLC-SG ali RBM-1 papirja nanesite piko (2 µl) radioaktivno označene raztopine.
English: which could interfere with this investigation.
Slovenian: ki nadzira postopek.
English: Ovaries
Slovenian: OVOJNINAH
English: NAME OF THE MEDICINAL PRODUCT Scintimun 1 mg kit for radiopharmaceutical preparation
Slovenian: IME ZDRAVILA Scintimun 1 mg komplet za pripravo radiofarmaka
English: Breast
Slovenian: Dojenje
English: Clinical efficacy In a randomised cross-over trial comparing blinded reading of Scintimun and 99mTc-White Blood Cells
Slovenian: V randomiziranem navzkrižnem preskušanju so primerjali zaslepljene slike, dobljene z zdravilom Scintimun in s 99mTc označenimi levkociti pri 119 bolnikih s sumom na osteomielitis.
English: INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA Komplet za pripravo radiofarmaka
English: When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.
Slovenian: Če ste v dvomih je pomembno, da se posvetujete s svojim zdravnikom nuklearne medicine,
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Scintimun 1 mg kit for radiopharmaceutical preparation Besilesomab
Slovenian: IME ZDRAVILA IN POT(I) UPORABE Scintimun 1 mg komplet za pripravo radiofarmaka besilesomab intravenska uporaba
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer of the biological active substance GLYCOTOPE Biotechnology GmbH
Slovenian: Ime in naslov izdelovalca biološke zdravilne učinkovine
English: Reconstitute Scintimun with its solvent first and then radiolabel with a sodium pertechnetate (99mTc) solution.
Slovenian: Najprej rekonstituirajte zdravilo Scintimun z njegovim vehiklom, nato ga radioaktivno označite z raztopino natrijevega pertehnetata (99mTc).
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Additional label after reconstitution and radiolabelling with sodium pertechnetate (99mTc) solution
Slovenian: Dodatna nalepka po rekonstituiranju in radioaktivnem označevanju z raztopino natrijevega pertehnetata (99mTc).
English: 10 min after the addition of pertechnetate (99mTc) the solution is ready for injection.
Slovenian: Raztopina je pripravljena za injiciranje 10 min po dodatku pertehnetata (99mTc).
English: An interval of at least 2 days must be observed between any previous scintigraphy with other technetium (99mTc)-labelled agents and administration of Scintimun.
Slovenian: Od prejšnje scintigrafske preiskave z uporabo s tehnecijem (99mTc) označenih snovi in uporabo zdravila Scintimun morata preteči vsaj 2 dneva.
English: Kit of two multidose vials of Scintimun and two vials of solvent.
Slovenian: Vsebuje dve večodmerni viali zdravila Scintimun in dve viali vehikla za zdravilo Scintimun.
English: Moreover you must avoid close contact with your child during the first 12 hours after the injection.
Slovenian: Z dojenjem nadaljujte v dogovoru z zdravnikom nuklearne medicine, ki nadzira postopek.Vendar se morate v prvih 12 urah po injiciranju izogibati tesnemu stiku s svojim otrokom.
English: Please refer to the SmPC.
Slovenian: Glejte povzetek glavnih značilnosti zdravila (SmPC).
English: What you need to know before you are given Scintimun
Slovenian: Kaj morate vedeti, preden boste prejeli zdravilo Scintimun Ne uporabljajte zdravila Scintimun:
English: How Scintimun is given
Slovenian: Kako boste prejeli zdravilo Scintimun
English: Bladder
Slovenian: Ščitnica
English: Solvent for Scintimun
Slovenian: Shranjevanje zdravila Scintimun
English: Anaphylactic/anaphylactoid reaction
Slovenian: Žilne bolezni hipotenzija pogosta
English: Patient preparation
Slovenian: Postopek priprave
English: Uncommon (may affect up to 1 in 100 people): Allergic reaction, including swelling of the face, hives (urticaria)
Slovenian: alergijska reakcija, ki povzroči otekanje obraza in koprivnico (urtikarijo) Redki (se lahko pojavijo pri največ 1 od 1000 bolnikov):
English: Kit of one multidose vial of Scintimun and one vial of solvent.
Slovenian: Vsebuje eno večodmerno vialo zdravila Scintimun in eno vialo vehikla za zdravilo Scintimun.
English: Small Intestine
Slovenian: Kosti Maternica
English: Only limited data is available about binding of technetium (99mTc) besilesomab to CarcinoEmbryonic
Slovenian: O vezavi tehnecijevega (99mTc) besilesomaba na tumorje, ki izražajo karcinoembrionalni antigen (CEA) in vivo, je podatkov malo.
English: The frequencies are based on the most recent clinical trial and non interventional safety survey.
Slovenian: V spodnji preglednici so navedeni neželeni učinki, razvrščeni po organskih sistemih MedDRA. Pogostnosti temeljijo na podatkih iz zadnjega kliničnega preskušanja zdravila.
English: PHARMACEUTICAL FORM AND CONTENTS Kit for radiopharmaceutical preparation Contains one multidose vial Scintimun and one vial solvent for Scintimun Contains two multidose vials Scintimun and two vials solvent for Scintimun
Slovenian: Komplet dveh večodmerni vial zdravila Scintimun in dveh vial vehikla za zdravilo Scintimun.
English: What Scintimun is and what it is used for
Slovenian: Kaj je zdravilo Scintimun in za kaj ga uporabljamo Scintimun je zdravilo, ki vsebuje protitelo (besilesomab).
English: The vials must not be opened.
Slovenian: Vial ne smete odpreti, dokler ne razkužite zamaška,
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial of Scintimun contains 1 mg of besilesomab
Slovenian: Ena viala zdravila Scintimun vsebuje 1 mg besilesomaba
English: Hypersensitivity, including angioedema, urticaria
Slovenian: Bolezni imunskega sistema anafilaktična/anafilaktoidna reakcija redka preobčutljivostna reakcija, vključno z angioedemom,
English: Scintimun is a sterile powder containing 1 mg of besilesomab per vial Scintimun.
Slovenian: NAVODILA ZA PRIPRAVO RADIOFARMAKOV Zdravilo Scintimun je sterilen prašek, ki v vsaki viali vsebuje 1 mg besilesomaba.
English: Ask your doctor if you are not sure.
Slovenian: Če ste negotovi, se posvetujte z zdravnikom,
English: A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
Slovenian: A. IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
English: CLINICAL PARTICULARS 4.1 Therapeutic indications This medicinal product is for diagnostic use only.
Slovenian: Zdravilo je samo za diagnostične namene.
English: Testis
Slovenian: Odmerjanje
English: B. PACKAGE LEAFLET
Slovenian: Skupna aktivnost traka
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON BOX contains Blue Box
Slovenian: PODATKI NA ZUNANJI OVOJNINI ŠKATLA
English: OTHER CIS bio international
Slovenian: DRUGI PODATKI CIS bio international
English: Reference male
Slovenian: Moda Priželjc
English: In general, patients were monitored for about 27 months, during which they took the medicine for about 24 months on average.
Slovenian: Na splošno so bolnike spremljali 27 mesecev; v tem času so zdravilo jemali povprečno 24 mesecev.
English: What measures are being taken to ensure the safe and effective use of Neparvis?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Neparvis?
English: Other information about Neparvis
Slovenian: Druge informacije o zdravilu Neparvis
English: This medicine is the same as Entresto, which is already authorised in the European Union (EU).
Slovenian: To zdravilo je enako zdravilu Entresto, ki je že odobreno v Evropski uniji (EU).
English: What is Neparvis and what is it used for?
Slovenian: Kaj je zdravilo Neparvis in za kaj se uporablja?
English: The full EPAR for Neparvis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Neparvis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Neparvis sacubitril / valsartan
Slovenian: Neparvis sakubitril/valsartan
English: Why is Neparvis approved?
Slovenian: Zakaj je bilo zdravilo Neparvis odobreno?
English: In the group treated with Neparvis, 21.8% (914 of 4,187) patients either died as a result of heart and circulation problems or were admitted to hospital with heart failure compared to 26.5% (1,117 of 4,212) patients treated with enalapril.
Slovenian: V skupini, zdravljeni z zdravilom Neparvis, je 21,8 % (914 od 4 187) bolnikov umrlo zaradi težav s srcem in obtokom ali pa so jih sprejeli v bolnišnico zaradi srčnega popuščanja v primerjavi s 26,5 % (1 117 od 4 212) bolnikov, ki so se zdravili z enalaprilom.
English: What are the risks associated with Neparvis?
Slovenian: Kakšna tveganja so povezana z zdravilom Neparvis?
English: It is not intended to provide practical advice on how to use Neparvis.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: A risk management plan has been developed to ensure that Neparvis is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Neparvis je bil pripravljen načrt obvladovanja tveganj.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Neparvis are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Neparvis večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: Neparvis is available as tablets (24 mg sacubitril / 26 mg valsartan, 49 mg sacubitril / 51 mg valsartan, and 97 mg sacubitril / 103 mg valsartan).
Slovenian: Zdravilo Neparvis je na voljo v obliki tablet (24 mg sakubitrila/26 mg valsartana, 49 mg sakubitrila/51 mg valsartana in 97 mg sakubitrila/103 mg valsartana).
English: What benefits of Neparvis have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Neparvis izkazalo v študijah?
English: This is a summary of the European public assessment report (EPAR) for Neparvis.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Neparvis.
English: The recommended starting dose is one tablet of Neparvis 49 mg / 51 mg twice a day and the dose is then doubled after 2 to 4 weeks to 97 mg / 103 mg twice a day.
Slovenian: Tablete zdravila Neparvis se jemljejo dvakrat na dan. Priporočeni začetni odmerek je ena tableta zdravila Neparvis 49 mg/51 mg dvakrat na dan, po 2 do 4 tednih pa se odmerek podvoji na 97 mg/103 mg dvakrat na dan.
English: Valsartan is an ‘angiotensin-II-receptor antagonist', which means that it blocks the action of a hormone called angiotensin II.
Slovenian: Valsartan je „antagonist receptorjev za angiotenzin II“, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
English: The effects of angiotensin II can be harmful in patients with heart failure.
Slovenian: Učinki angiotenzina II so pri bolnikih s srčnim popuščanjem lahko škodljivi.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Neparvis, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: It must not be taken by patients who have suffered angioedema, those who have severe liver disease or by women who are pregnant.
Slovenian: Zdravila ne smejo jemati bolniki, ki so že imeli angioedem, bolniki s težko boleznijo jeter in nosečnice.
English: Neparvis has been shown to be effective in treating heart failure in one main study.
Slovenian: Zdravilo Neparvis se je izkazalo kot učinkovito pri zdravljenju srčnega popuščanja v eni glavni študiji.
English: Neparvis can only be obtained with a prescription.
Slovenian: Izdaja zdravila je le na recept.
English: The company that makes Entresto has agreed that its scientific data can be used for Neparvis (‘informed consent').
Slovenian: Družba, ki proizvaja zdravilo Entresto, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Neparvis („uporaba dokumentacije s soglasjem“).
English: The main study found that Neparvis reduced deaths from heart and circulation problems or hospital admissions for heart failure.
Slovenian: V glavni študiji so ugotovili, da zdravilo Neparvis zmanjša število smrti, ki so posledica težav s srcem in obtokom, ter število sprejemov v bolnišnico zaradi srčnega popuščanja.
English: Neparvis must not be taken with medicines known as ACE inhibitors (which are used to treat heart failure and high blood pressure).
Slovenian: Zdravilo Neparvis se ne sme jemati skupaj z zdravili, znanimi kot zaviralci ACE (ki se uporabljajo za zdravljenje srčnega popuščanja in visokega krvnega tlaka).
English: The most common side effects with Neparvis (which may affect more than 1 in 10 people) are high blood potassium levels, low blood pressure and the kidneys working less well.
Slovenian: Najpogostejši neželeni učinki zdravila Neparvis (ki lahko prizadenejo več kot 1 osebo od 10) so visoka koncentracija kalija v krvi, nizek krvni tlak in slabše delovanje ledvic.
English: Natriuretic peptides also reduce blood pressure and protect the heart from developing fibrosis (scar tissue) that occurs in heart failure.
Slovenian: Natriuretični peptidi tudi zmanjšajo krvni tlak in srce ščitijo pred razvojem fibroze (nastanka brazgotin), ki se pojavi pri srčnem popuščanju.
English: The serious side effects of Neparvis in the main study were similar to those of enalapril, which is already authorised for use in heart failure.
Slovenian: Resni neželeni učinki zdravila Neparvis v glavni študiji so bili podobni neželenim učinkom enalaprila, ki je že odobren za uporabo pri srčnem popuščanju.
English: The two active substances in Neparvis, sacubitril and valsartan, work in different ways.
Slovenian: Zdravilni učinkovini v zdravilu Neparvis, sakubitril in valsartan, delujeta na različna načina.
English: For practical information about using Neparvis, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Neparvis naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone's harmful effects on the heart and it also reduces blood pressure by allowing blood vessels to widen.
Slovenian: Z blokado receptorjev, na katere se običajno veže angiotenzin II, valsartan prepreči škodljive učinke hormona na srce in s širjenjem žil zmanjša krvni tlak.
English: Neparvis is a heart medicine that contains the active substances sacubitril and valsartan.
Slovenian: Neparvis je zdravilo za srce, ki vsebuje zdravilni učinkovini sakubitril in valsartan.
English: For more information about treatment with Neparvis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Neparvis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: How is Neparvis used?
Slovenian: Kako se zdravilo Neparvis uporablja?
English: For the full list of all side effects reported with Neparvis, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Neparvis, glejte navodilo za uporabo.
English: In the study, Neparvis was compared to enalapril, another medicine used for heart failure.
Slovenian: V tej študiji so zdravilo Neparvis primerjali z enalaprilom, drugim zdravilom za zdravljenje srčnega popuščanja.
English: How does Neparvis work?
Slovenian: Kako zdravilo Neparvis deluje?
English: The study was stopped early because there was compelling evidence that Neparvis was more effective than enalapril.
Slovenian: Študijo so zaradi trdnih dokazov, da je zdravilo Neparvis učinkovitejše od enalaprila, predčasno prekinili.
English: A potentially severe side effect, angioedema (rapid swelling of deeper skin tissues as well as the tissues around the throat, causing breathing difficulty), can occur uncommonly (affecting fewer than 1 in 100 people).
Slovenian: Občasno se lahko pojavi potencialno resen neželeni učinek (ki prizadene manj kot 1 osebo od 100), tj. angioedem (hitro otekanje globokih kožnih tkiv in tkiv okrog grla, kar povzroči težave z dihanjem).
English: Cutaneous use Multidose container with airless pump (PP/TPO/HDPE)
Slovenian: Večodmerni vsebnik z brezzračno črpalko (PP/TPO/HDPE)
English: 1 pump
Slovenian: Stična ovojnina
English: Pack size
Slovenian: Velikost pakiranja
English: 3 inhalers with 60 actuations
Slovenian: 3 inhalatorji s 60 odmerki
English: Immediate Packaging Pack size
Slovenian: Pot uporabe Stična ovojnina Velikost pakiranja
English: The evaluation was withdrawn after ‘day 90'.
Slovenian: Postopek ocenjevanja je bil umaknjen po „dnevu 90“.
English: 17 December 2009 EMA/809491/2009 EMEA/H/C/471
Slovenian: EMEA/H/C/471
English: Abilify has been authorised since June 2004.
Slovenian: Zdravilo Abilify je odobreno od junija 2004.
English: The study lasted up to a year and involved 1,076 patients, some of whom had completed one of the three short-term studies.
Slovenian: Študija je trajala do enega leta in je vključevala 1 076 bolnikov, od katerih so nekateri zaključili eno od treh kratkotrajnih študij.
English: The main measure of effectiveness was the change in symptoms over the six weeks of dual treatment.
Slovenian: Glavno merilo učinkovitosti je bila sprememba simptomov v šestih tednih dvojnega zdravljenja.
English: Its exact mechanism of action is unknown, but it attaches to several different receptors on the surface of nerve cells in the brain.
Slovenian: Natančen mehanizem delovanja ni znan, vendar pa se zdravilo veže z več različnimi vrstami receptorjev na površini živčnih celic v možganih.
English: After the CHMP had assessed the company's responses to the questions, there were still some unresolved issues.
Slovenian: Potem ko je CHMP ocenil odgovore družbe na vprašanja, so nekatera vprašanja še vedno ostala nerešena.
English: Major depressive episodes are periods of depressed mood or loss of interest in everyday activities that last for at least two weeks in patients with major depression.
Slovenian: Večje epizode depresije so obdobja potrtosti ali izgube zanimanja za vsakodnevne aktivnosti, ki trajajo vsaj dva tedna pri bolnikih s hudo depresijo.
English: The full European Public Assessment Report for Abilify is available here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Abilify je na voljo tukaj.
English: This means that the CHMP had evaluated the documentation provided by the company and formulated lists of questions.
Slovenian: To pomeni, da je CHMP ocenil dokumentacijo, ki jo je predložila družba, in pripravil seznam vprašanj.
English: The company presented the results of three short-term and one long-term study to support its application.
Slovenian: Družba je v podporo svoji vlogi predložila rezultate treh kratkotrajnih študij in ene dolgotrajne študije.
English: Abilify was not compared with any other treatments in this study and the patients knew which medicines they were taking.
Slovenian: Zdravila Abilify niso primerjali z drugimi zdravili v tej študiji, bolniki pa so vedeli, katera zdravila jemljejo.
English: This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other.
Slovenian: S tem se prekine prenos signalov med možganskimi celicami preko „živčnih prenašalcev“ - kemičnih snovi, ki omogočajo komunikacijo med živčnimi celicami.
English: At the start of the study, the patients were put on an eight-week course of an antidepressant (escitalopram, sertraline, venlafaxine, fluoxetine or paroxetine).
Slovenian: Na začetku študije so bolnikom predpisali osemtedensko zdravljenje z antidepresivom (escilatopram, sertralin, venlafaksin, fluoksetin ali paroksetin).
English: There are no consequences on the use of Abilify in its authorised indications, for which the balance of benefits and risks remains unchanged.
Slovenian: Umik nima nobenih posledic za uporabo zdravila Abilify za odobrene indikacije, pri katerih ostaja razmerje med koristmi in tveganji nespremenjeno.
English: The short-term studies were ‘double-blind', which means that neither the patients nor the investigators knew which patients were receiving Abilify and which were receiving placebo.
Slovenian: Kratkotrajne študije so bile „dvojno slepe“, kar pomeni, da niti bolniki niti raziskovalci niso vedeli, kateri bolniki so prejemali zdravilo Abilify in kateri placebo.
English: Aripiprazole is thought to act mainly by being a ‘partial agonist' for the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).
Slovenian: Aripiprazol domnevno deluje predvsem kot „delni agonist“ za receptorje za živčna prenašalca dopamin in 5hidroksitriptamin (imenovan tudi serotonin).
English: The CHMP was concerned over the patients included in the studies, as it was not clear whether they all had resistant depression, defined as failure to respond to at least two previous antidepressants.
Slovenian: CHMP je izrazil zadržke glede bolnikov, vključenih v študijah, saj ni bilo jasno, ali imajo vsi odporno depresijo, opredeljeno kot neodzivno na vsaj dve predhodni zdravljenji z antidepresivi.
English: It is available as tablets, orodispersible tablets (tablets that dissolve in the mouth), an oral solution and a solution for injection.
Slovenian: Na voljo je v obliki tablet, orodisperzibilnih tablet (tablet, ki se raztopijo v ustih), peroralne raztopine in raztopine za injiciranje.
English: The 1,090 patients who did not respond to this antidepressant then added either Abilify or placebo (a dummy treatment).
Slovenian: Nato je 1 090 bolnikov, ki se na ta antidepresiv ni odzvalo, prejelo še zdravilo Abilify ali placebo (zdravilo brez zdravilne učinkovine).
English: Abilify is a medicine that contains the active substance aripiprazole.
Slovenian: Abilify je zdravilo, ki vsebuje zdravilno učinkovino aripiprazol.